Skip to main content
. 2015 Mar 19;4(6):e1009285. doi: 10.1080/2162402X.2015.1009285

Table 2.

Univariate analysis of overall survival and immune parameters

Marker Tumor Stroma
N (%) Median OS 95%CI P-value* N (%) Median OS 95%CI P-value*
CD3
 Low 54 (25) 14.3 (9.4, 24.9) 0.57 143 (67) 16.2 (13.8, 19.4) 0.52
 High 162 (75) 16.8 (15.0, 19.8) 72 (33) 17.4 (15.0, 23.3)
CD4
 Low 113 (52) 15.2 (10.6, 19.2) 0.04 28 (13) 15.0 (7.4, 21.9) 0.26
 High 105 (48) 17.0 (14.5, 24.8) 188 (87) 17.0 (14.9, 20.1)
CD8
 Low 86 (40) 14.7 (12.0, 19.8) 0.061 94 (44) 18.9 (14.7, 23.0) 0.68
 High 131 (60) 17.0 (14.5, 21.0) 120 (56) 15.3 (12.5, 18.1)
CD45RO
 Low 93 (61) 16.3 (14.5, 23.8) 0.98 133 (86) 16.2 (14.6, 19.4) 0.72
 High 60 (39) 15.0 (9.8, 20.9) 21 (14) 17.4 (10.1, 38.9)
CD20
 Low 128 (59) 14.5 (10.5, 16.8) 0.003 94 (44) 15.0 (11.4, 18.9) 0.21
 High 89 (41) 20.7 (16.3, 26.9) 119 (56) 18.1 (15.2, 23.3)
FoxP3
Low 142 (65) 16.1 (14.0, 19.9) 0.58 140 (66) 16.2 (14.3, 20.1) 0.87
 High 75 (35) 16.8 (11.4, 21.1) 72 (34) 17.0 (15.0, 21.1)
CD68
 Low 172 (79) 16.3 (14.3, 19.8) 0.87 22 (10) 22.0 (16.2, 61.1) 0.067
 High 47 (21) 16.9 (10.9, 23.4) 193 (90) 16.3 (14.5, 19.2)
CD163
 Low 112 (53) 19.1 (15.1, 23.4) 0.49 133 (67) 18.1 (15.1, 22.4) 0.12
 High 98 (47) 15.0 (10.6, 18.1) 66 (33) 14.5 (10.3, 17.0)
IL-7R
 Low 116 (53) 19.3 (16.3, 26.4) 0.007  
 High 103 (47) 14.0 (10.6, 18.1)
IL-12Rβ2
 Low 112 (75) 15.4 (13.8, 19.1) 0.067  
 High 38 (25) 19.9 (14.5, 41.6)
CCR7
 Low 123 (79) 15.2 (14.0, 18.1) 0.16  
 High 33 (21) 28.1 (15.0, 45.5)
CXCL12
 Low 55 (36) 15.4 (11.4, 18.1) 0.49  
 High 99 (64) 16.8 (15.0, 23.4)
CXCR4
 Low 104 (69) 15.0 (12.5, 17.6) 0.081  
 High 46 (31) 21.9 (12.4, 35.2)

Abbreviations: CI = confidence interval; FoxP3 = forkhead box P3; IL-7R = interleukin-7 receptor; IL-12Rβ2 = interleukin-12 receptor β2; OS = overall survival (months).

Statistical analysis was performed by log-rank test; significant P-values (<0.05) are shown in bold type.

Stroma not applicable for this marker.

*

Adjusted for search of optimal cut-point.